Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | S100A4 | P26447 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL21383687 | 0.98 | TDP1 (0.62) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL120973 | 0.83 | TDP1 (0.64) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL5785580 | 0.82 | TDP1 (0.58) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL29188677 | 0.82 | TDP1 (0.62) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL11015121 | 0.81 | MAPT (0.56) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL4607929 | 0.81 | PDE7A (0.55) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL1561802 | 0.80 | TSHR (0.56) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL3973537 | 0.78 | MAPT (0.69) | TDP1TSHRMAPTALDH1A1LMNA | |
| SCHEMBL165733 | 0.78 | CYP19A1 (0.49) | TDP1TSHRMAPTALDH1A1MAPK1 | |
| SCHEMBL121896 | 0.78 | TDP1 (1.00) | TDP1TSHRMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109467535-B | Preparation method of fenbendazole | 江苏宝众宝达药业有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-111269213-A | Benzopyrazines compound and preparation method and application thereof | 嘉兴秀君医疗器械有限公司 | 2020-06-12 | — | — | CN | claimed |
| US-12589156-B2 | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) | ARVINAS OPERATIONS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12559457-B2 | Sulfonamide derivatives for protein degradation | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4683909-A2 | ATM KINASE INHIBITORS | Eberhard Karls Universität Tübingen (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-20260015328-A1 | ATM KINASE INHIBITORS | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2026-01-15 | — | — | US | disclosed |
| EP-4665456-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | Arvinas Operations, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12474348-B2 | Complexes between CD40 and compounds comprising benzimidazole moieties | UCB Biopharma SRL (BE) | 2025-11-18 | — | — | US | disclosed |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250228952-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | ARVINAS OPERATIONS, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025072629-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | ARVINAS OPERATIONS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| EP-1341771-A2 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TIE-2 AND/OR VEGFR-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-09-10 | — | — | EP | disclosed |
| WO-2003010146-A1 | COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF | NEURO3D (FR) | 2003-02-06 | — | — | WO | disclosed |
| WO-2002044156-A2 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TIE-2 AND/OR VEGFR-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-06-06 | — | — | WO | disclosed |
| EP-0303429-A2 | Second harmonic generation with 5-chloro-2-nitroaniline | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-02-15 | — | — | EP | disclosed |
| EP-0041042-B1 | AZO COMPOUNDS | CIBA-GEIGY AG (CH) | 1984-12-05 | — | — | EP | disclosed |
| EP-0041042-A1 | Azo compounds | CIBA-GEIGY AG (CH) | 1981-12-02 | — | — | EP | disclosed |
| US-4185018-A | Process for producing benzofurazan-1-oxides | CIBA-GEIGY CORPORATION (US) | 1980-01-22 | — | — | US | disclosed |
| US-RE28939-E | MUSCLE RELAXANTS, ANALGESICS | SMITHKLINE CORPORATION (US) | 1976-08-24 | — | — | US | disclosed |
| US-3932662-A | ANTHELMINTICS, PYRUVOYL CHLORIDE PHENYLHYDRAZONES | THE UPJOHN COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | TDP1 3091/4885TSHR 3866/4885MAPT 2761/4885 |
| US-12559457-B2 | Sulfonamide derivatives for protein degradation | CRBN, ADRM1, RBX1 | TDP1 2692/4885TSHR 1520/4885MAPT 3181/4885 |
| US-20250228952-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | LRRK2, PINK1, PSMC1 | TDP1 2547/4885TSHR 3987/4885MAPT 888/4885 |
| US-12589156-B2 | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) | LRRK2, SNCA, PARK7 | TDP1 3310/4885TSHR 3129/4885MAPT 250/4885 |
| US-20260015328-A1 | ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | TDP1 265/4885TSHR 728/4885MAPT 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.